Apollo Hospitals Partners with Precisio Biotix to Develop Lysin-Based Antimicrobials Against AMR
Apollo Hospitals has partnered with Precisio Biotix to advance lysin-based antimicrobials in India, aiming to combat antimicrobial resistance (AMR). This collaboration focuses on translational research, clinical validation, and deployment of lysin therapies targeting drug-resistant infections, including chronic and hospital-acquired cases. Lysins are precision enzymes that disrupt pathogens without promoting resistance. The partnership also plans to publish a white paper on lysin therapies and AMR management, emphasizing innovative approaches to improve patient care.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (78/100). Lens Score 38/100.
Outlets measured: businessstandard, thehindu, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (78–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 21 Jul, 10:54 am. Other outlets followed.